
Oncorus Net Income | ONCR
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Oncorus
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -77.4 M | -64.8 M | -48.3 M | -30.7 M | -18 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -18 M | -77.4 M | -47.8 M |
Quarterly Net Income Oncorus
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -30.9 M | - | -19.6 M | -19.1 M | -17.8 M | - | -16.7 M | -15.5 M | -12.7 M | - | -19.5 M | -9.37 M | -7.83 M | - | -7.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -7.57 M | -30.9 M | -16.1 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Geron Corporation
GERN
|
-83.5 M | $ 0.87 | -4.76 % | $ 580 M | ||
|
Pharming Group N.V.
PHAR
|
33 M | $ 11.54 | -5.18 % | $ 7.95 B | ||
|
Phathom Pharmaceuticals
PHAT
|
-221 K | $ 4.65 | -8.46 % | $ 339 M | ||
|
Genmab A/S
GMAB
|
7.84 B | $ 50.36 | -1.93 % | $ 3.26 B | ||
|
Gossamer Bio
GOSS
|
-170 M | $ 10.69 | -4.81 % | $ 2.44 B | ||
|
Grifols, S.A.
GRFS
|
213 M | $ 8.14 | -0.73 % | $ 5.53 B | ||
|
Liquidia Corporation
LQDA
|
-68.9 M | $ 54.39 | -3.96 % | $ 4.68 B | ||
|
GlaxoSmithKline plc
GSK
|
6.29 B | $ 47.8 | -0.05 % | $ 194 B | ||
|
MediciNova
MNOV
|
12 M | $ 1.3 | 2.36 % | $ 63.8 M | ||
|
PTC Therapeutics
PTCT
|
683 M | $ 56.23 | -3.59 % | $ 4.47 B | ||
|
Pulmatrix
PULM
|
-1.17 M | $ 1.24 | -12.34 % | $ 4.53 B | ||
|
InflaRx N.V.
IFRX
|
-45.6 M | $ 1.05 | -3.67 % | $ 70.7 M | ||
|
Immunome
IMNM
|
-212 M | $ 15.69 | -5.54 % | $ 1.37 B | ||
|
Immuron Limited
IMRN
|
-5.22 M | $ 0.9 | 5.87 % | $ 208 M | ||
|
Incyte Corporation
INCY
|
1.29 B | $ 114.5 | -1.19 % | $ 22.4 B | ||
|
INmune Bio
INMB
|
-46 M | $ 0.82 | -8.41 % | $ 20.3 M | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
57.2 B | $ 14.88 | 0.24 % | $ 12.4 B | ||
|
Regeneron Pharmaceuticals
REGN
|
4.5 B | $ 920.38 | -0.22 % | $ 96.3 B | ||
|
Ionis Pharmaceuticals
IONS
|
-381 M | $ 26.58 | -2.37 % | $ 4.25 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
1.24 B | $ 1.06 | -10.92 % | $ 48.4 M | ||
|
Ironwood Pharmaceuticals
IRWD
|
24 M | $ 4.68 | -0.53 % | $ 757 M | ||
|
Kala Pharmaceuticals
KALA
|
-27 M | $ 2.73 | -9.61 % | $ 22.2 M | ||
|
Intellia Therapeutics
NTLA
|
-413 M | $ 10.02 | 5.24 % | $ 1.09 B | ||
|
Adagene
ADAG
|
-17.6 M | $ 1.8 | -10.56 % | $ 106 M | ||
|
Denali Therapeutics
DNLI
|
-513 M | $ 18.43 | 1.29 % | $ 3.18 B | ||
|
Pfizer
PFE
|
7.77 B | $ 27.4 | -0.62 % | $ 156 B | ||
|
Amarin Corporation plc
AMRN
|
-38.8 M | $ 10.56 | -6.26 % | $ 4.38 B | ||
|
ImmuCell Corporation
ICCC
|
-1.04 M | $ 11.08 | -0.81 % | $ 100 M | ||
|
Editas Medicine
EDIT
|
-160 M | $ 1.63 | -4.68 % | $ 145 M | ||
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
59 M | $ 93.83 | 0.32 % | $ 6.96 B | ||
|
Agios Pharmaceuticals
AGIO
|
-413 M | $ 27.54 | -4.24 % | $ 1.6 B | ||
|
Royalty Pharma plc
RPRX
|
771 M | $ 68.45 | 1.08 % | $ 29.4 B | ||
|
Equillium
EQ
|
-22.4 M | $ 1.06 | -5.36 % | $ 60.7 M | ||
|
Black Diamond Therapeutics
BDTX
|
22.4 B | $ 1.32 | -5.04 % | $ 75.1 M | ||
|
Abeona Therapeutics
ABEO
|
-71.2 M | $ 2.42 | -1.17 % | $ 128 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
391 M | $ 17.1 | -2.79 % | $ 2.88 B | ||
|
Atossa Therapeutics
ATOS
|
-34.8 M | $ 1.6 | -8.86 % | $ 13.8 M | ||
|
Cleveland BioLabs, Inc.
CBLI
|
-2.4 M | - | -7.31 % | $ 49 M | ||
|
Rhythm Pharmaceuticals
RYTM
|
-197 K | $ 112.31 | -3.84 % | $ 7.3 B | ||
|
Five Prime Therapeutics, Inc.
FPRX
|
-84.3 M | - | - | $ 1.77 B | ||
|
ADC Therapeutics SA
ADCT
|
-143 M | $ 1.29 | -2.28 % | $ 164 M | ||
|
Harmony Biosciences Holdings
HRMY
|
159 M | $ 32.58 | -1.21 % | $ 1.87 B | ||
|
Ardelyx
ARDX
|
-62 M | $ 2.99 | -2.25 % | $ 721 M | ||
|
Akebia Therapeutics
AKBA
|
-5.3 M | $ 0.39 | -8.41 % | $ 100 M | ||
|
Alector
ALEC
|
-143 M | $ 2.34 | 1.52 % | $ 241 M | ||
|
ALX Oncology Holdings
ALXO
|
-102 M | $ 1.06 | 3.43 % | $ 56.9 M | ||
|
Amneal Pharmaceuticals
AMRX
|
72.1 M | $ 21.12 | -1.26 % | $ 6.62 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-33.5 M | $ 4.03 | -1.11 % | $ 772 M | ||
|
Agenus
AGEN
|
-3.08 M | $ 5.97 | -2.85 % | $ 178 M | ||
|
PolyPid Ltd.
PYPD
|
-34.2 M | $ 6.1 | -6.87 % | $ 99.7 M |